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Abstract
Introduction: This article presents the case of a 26-year-old woman with tongue cancer. The median age at the
diagnosis of the tongue’s cancer is 61 years. Only approximately 2% of patients are diagnosed before the age of 35.
Case presentation: Our patient survived acute myeloid leukemia (AML) before her second year. She had been
having recurrent, poorly healing aphtae on the right side of the tongue for a period of months before the
symptoms of the tongue cancer appeared. As a treatment a partial glossectomy was conducted on the right side
and a neck dissection of levels I-III. Than a reconstruction of the tongue with a radialis free vascularised flap from
left side was performed.
Discussion: It should be always looked for the causal factor in young patients with a neoplasm. There is strong
evidence for second malignant neoplasms in survivors of childhood cancer.
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Background
The morbidity of malignant tumors in young patients is
low (only approximately 2 percent of patients diagnosed
with tongue cancer are below the age of 35). This was
the case of this patient who suffered from an acute mye-
loid leukemia before she turned two. It is known that
survivors of childhood cancer are at risk of developing a
second malignant neoplasm.
Case presentation
Introduction
Squamous cell carcinoma (SCC) of the tongue is the
most frequent intra oral head and neck cancer.
European statistics indicate an incidence of around 10–
20 per 100 000 of the population. In Western Europe a
decrease has been seen in males, contrary to the increase
in female subjects that has been evident over the last
decade. Many other world regions are finding an general
increase of the incidence of oral cancer. [1] The median
age at the diagnosis of the tongue’s cancer is 61 years.
Only approximately 2% of patients are diagnosed before
the age of 35 and another 7% before the age of 45, this
despite the fact that there is an increasing trend in the
prevalence of tongue SCC. [2-4].
In the literature only three studies have evaluated oral
tongue SCC in patients younger than 30 years old. The
study published by Soudry et al. [4] in 2010 as well as
two further studies [5,6] were done nearly 30 years ago.
Apart from the possibility of a potential genetic ten-
dency there are some well known carcinogens in head
and neck squamous cell carcinoma (HNSCC) such as
tobacco, alcohol, viruses like the human papilloma virus
(HPV), herpes simplex virus (HSV), Epstein-Barr virus
(EBV), as well as immunosuppression, polymorphism of
interleukin 6 (IL6) and tumor necrosis factor (TNF) [7]
and inherited syndromes, e.g. Fanconi anemia, Aplastic
anemia [8] that all may play a role in the carcinogenesis
process. These factors may be present as single factors,
but may in combination play a more compelling role in
the early development of HNSCC.
As for other intra oral sites SSC of the tongue is often
associated with other potentially malignant or premalig-
nant lesions and conditions such a leukoplakia, erosive
lichen planus as well as atrophic glossitis. Poor oral hy-
giene is also reported to play a role. [9-11].
In young patients the main causal factor of oropharyn-
geal SCC appears to be HPV infection, associated mostly
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with cancer of the tonsils. [12] Marijuana remains an-
other possible contributing factor and it would seem
that anemia is a co-factor, not only regarding the devel-
opment, but also regarding prognosis. In contrary to
their older counterparts young patients with SCC rather
tend to be non-smokers, non-drinkers. [13-15] Patients
younger than 30 years exhibit a significantly increased
chromosome fragility compared to other patients follow-
ing exposure to mutagen, [16] which may explain why
environmental exposure to smoke probably plays a role
in non-smokers.
A separate risk group consists of patients with a sec-
ond primary cancers in survivors of childhood cancer. It
is known that cancer patients have some risk of second
synchronous or metachronous primary tumor. [16-19].
Case report
A 26 year-old patient presented herself at the Oral Sur-
gery Division of the University Hospital Zurich with a
main complaint of a tongue lesion.
For the last 4 months she observed an alteration on
the right side of the tongue, displaying alarming growth
over a three week period. The lesion was painful when
the patient moved her tongue or while eating. She fur-
ther mentioned also having recurrent, poorly healing
aphtae on the right side of the tongue for a period of
months before the current symptoms presented.
Regarding her medical history she suffered of acute
myeloid leukemia (AML) before the age of 2 and 8 years
ago she had an incident of a cerebral venous sinus
thrombosis. Currently she suffers from epilepsy, but she
hasn’t had any symptoms for a long time. She has no
known allergies, takes no medicine, no antiepileptic
drugs, has been smoking for 8 years 2–3 cigarettes per
day and she doesn’t drink alcohol. No weight changes or
night sweats were noted.
On examination the patient showed a symmetric face
and normal skin color, motor and sensory cranial nerve
functions were within normal range. No lymph nodes
were palpable in her neck on both sides.
On intra oral examination we found a tumor in the
middle third position of the right side of the tongue.
The size of the tongue lesion was about 15x20x15 mm
(width, length, depth), appearing to be exophytic, with a
Figure 1 Lateral view of 2 cm ulcer on middle third of the right side of the tongue.
Figure 2 Frontal view of 2 cm ulcer on middle third of the right side of the tongue.
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central ulcer appearing to infiltrate the tongue muscula-
ture that appeared to be relatively well demarcated
(Figures 1 and 2). The oral mucosa showed signs of leu-
koedema and maceration on the right buccal mucosa
and on the lower lip due to a self inflicted chewing habit.
No limitation of the mouth opening was observed and a
normal dentition was apparent.
Considering the clinical appearance and the history of
the quick growth of the tongue’s lesion we postulated a
malignant alteration and on the day of the first examin-
ation a biopsy under local anesthesia was performed.
The histopathology showed a moderately differentiated,
squamous cell carcinoma with surrounding chronic in-
flammation. The patient was transferred to the Cranio-
Maxillofacial and Oral Surgery Division of the University
Hospital Zurich. A MRI (Magnetic Resonance Imaging)
as well as a PET (Positron Emission Tomography) scan
was performed as per standard oncological staging. No
Figure 3 Completed right sided neck dissection.
Figure 4 Raised radial forearm free flap.
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evidence of locoregional lymphatic spread or distant me-
tastasis could be found which led to a cT2N0M0 staging.
Eight days after the first examination at the same depart-
ment a partial glossectomy was conducted on the right
side and neck dissection of levels I-III (Figure 3). Due to
the extent of the resection a reconstruction of the
tongue with a radialis free vascularised flap from left side
was performed (Figures 4, 5 and 6). Full thickness skin
graft from the medial side of the upper arm was used to
cover the donor site (Figures 7 and 8).
The histological analysis confirmed the presence of a
moderately differentiated squamous cell carcinoma of
the right tongue. The surgical excision margins were all
safely clear of tumor and no positive lymph nodes were
noted with a final staging of pT1pN0(0/28)pR0. Due to
the R0 resection, no positive lymph nodes and absence
of histological risk factors no further treatment was
recommended. A standardized follow up protocol was
followed.
Discussion
As the median age at diagnosis of tongue cancer is
61 years and only 2% of patients are diagnosed before
the age of 35 these are thus rare occurrences and war-
rants further attention.
Our 26-year old patient survived acute myeloid
leukemia (AML) before her second year. These
Figure 6 Donor site 3 weeks post operatively.
Figure 7 3 week post operative view showing good tongue
mobility.
Figure 5 Direct post operative donor site.
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improved survival rates will become more common as
drug therapies improve.
The main treatment for AML is chemotherapy that
usually comprises of different phases: In the first phase
(induction), a combination of chemotherapy drugs is
given to the patient to destroy the leukemia cells and en-
able the bone marrow to regain normality. The treat-
ment is continued for a period of time even after there
are no more signs of leukemia in the blood or bone mar-
row examinations to rule out any recurrence. This post-
remission treatment usually involves two or three further
cycles of chemotherapy. A bone marrow transplantation,
following the standard chemotherapy, is applied only for
children with AML at high risk of recurrence. AML may
at times develop in the central nervous system that can
be prevented by injecting chemotherapy drugs directly
into the spinal fluid during a lumbar puncture. This
chemotherapy is usually given after each of the two pre-
viously mentioned courses of chemotherapy. Occasion-
ally, radiotherapy may play a role in disease affecting the
brain.
Chemotherapy drugs and radiation are known for their
long term carcinogenic effects; therefore second malig-
nancies are one of the most serious side effects of treat-
ment of childhood cancer survivors. The risk of
developing a second malignancy in 20-year survivors,
following a first childhood malignancy, is estimated at
Figure 8 Lateral view 3 weeks post operatively.
Table 1 A cumulative incidence of second neoplasms
20 years from original cancer diagnosis
Cumulative incidence
of second malignant
neoplasm at 20 y, %
Excess absolute
risk/1000 person-years
of follow-up
Overall 3.18 1.88
Hodgkin 7.63 5.13
Soft tissue
sarcoma
3.98 2.33
Neuroblastoma 1.87 0.95
Kidney tumor 1.62 1.01
Leukemia 2.05 1.20
Bone cancer 3.28 1.79
Central neural system 2.14 1.13
Non-Hodgkin 1.87 0.89
Excess absolute risk is determined by subtracting the expected number of
malignancies in the cohort from the observed number, dividing the difference
by the person-years of follow-up, and multiplying by 1000.
Table 2 Risk according to type of second cancer
Standardized Incidence Ratio
Overall 6.38
Bone cancer 19.14
Breast cancer 16.18
Thyroid cancer 11.34
Central neural system 9.85
Leukemia 6.86
Soft-tissue sarcoma 6.33
Melanoma 4.04
Lymphoma 1.51
Other 4.01
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3-12%, [20] this represents a 10 fold [21] or 10–20 fold
[18] increase in survivors of childhood AML as compared
to the general population.
On the one hand cumulative incidence of second ma-
lignant neoplasm (SMN) varies depending on the ori-
ginal cancer diagnosis. Assessment of second neoplasms
according to the Childhood Cancer Survivor Study
(CCSS), published by Neglia at al 2001, demonstrates
that SMNs are significantly associated with initial cancer
diagnosis of Hodgkin disease or soft tissue sarcoma.
Table 1 derived from Joseph P. Neglia 2001 [17].
On the other hand incidence of the SMN depends on
the treatment of the primary malignancy. [22] Radiation
therapy is a major cause of SMN. [23,24] Eighty to
ninety percent of SMNs following the radiation therapy
occurs within the radiation field. Typical SMNs after
Radiotherapy are skin cancer, thyroid cancer and breast
cancer (in female survivors of Hodgkin’s Lymphoma, 57-
fold risk compared with the general population) [24].
In contrary to the radiotherapy associated solid
tumors, chemotherapy mostly causes hematologic sec-
ond malignancies. [17].
Assessment of risk according to type of second cancer
demonstrated that the highest risks were seen for sec-
ondary tumors involving bone, breast, thyroid and cen-
tral nervous system.
Table 2 derived from Joseph P. Neglia 2001 [17].
According to CCSS beside second neoplasm’s other
therapy - related outcomes are early death, organ dys-
function such as cardiac, pulmonary, and endocrine,
gonal, decreased fertility reduced growth and impaired
intellectual function.
Although the role of the chemotherapy and radiation
is well established, variability between individuals exist,
which suggests a role for genetic variation in the suscep-
tibility to genotoxic exposures. This individual variability
is probably related to polymorphism genes that regulate
the availability of the active drug metabolite or other
mechanisms responsible for DNA repair. Polymorphism
in genes implicated in drug metabolism and transport
are relevant for disease-free survival and drug toxicity.
[25] Variation in DNA repair plays a part in susceptibil-
ity to de-novo cancer and probably modifies the risk of
second primary cancers after exposure to radiation and
chemotherapy [26].
In conclusion it can be stated that improvements in
the treatment of malignancies of childhood thankfully
leads to more survivors. This is however slightly shaded
by the fact that these patients may develop a second ma-
lignancy later in life. It is conceded that this may be a
multi factorial process with other risk factors like genetic
predisposition, environmental exposure, hormonal and
alterations in immune function playing a up to yet un-
defined role. By optimizing early diagnosis as well as
treatment strategies the life span of these patients may
be prolonged further.
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